|
Fig. 5 Maternal Ship2a attenuates FGF receptor-mediated pMAPK activation in the pre-gastrula embryo. (A-F) Anti-pMAPK immunoreactivity in oblong-sphere stage (3.7-4 hpf) WT, DMSO-treated control, maternal ship2a morphant and SU5402-treated embryos. (A,B) In WT and DMSO-treated control embryos, pMAPK is restricted to the dorsal side of the embryo. (C,D) Knockdown of maternal Ship2a causes a dramatic ventralward expansion of the pMAPK expression domain. (E,F) Inhibition of FGFR activity with 60 μM SU5402 completely inhibits pMAPK activation in both WT and maternal ship2a-morphant embryos. Confocal projections. Animal pole views with dorsal to the right.